



2026 World Conference on Lung Cancer

SEPTEMBER 12 – 15, 2026 | SEOUL, REPUBLIC OF KOREA

A Global Collaborative Survey of Clinician Perspectives on Maintenance Tyrosine Kinase Inhibitors in Unresectable EGFR-mutant Stage III Non-Small Cell Lung Cancer

Chia Ching Lee¹, Valeria Dionisi², Neal McCall³, Sarah Bowen Jones⁴, Jose Carlos Benitez⁵, Maaike van den Bos⁶, Neil Wallace⁷,
Guncha Maheshwari⁸, Jinyong Kim⁹, Sehhoon Park⁹, Kristin Higgins¹⁰, Anne-Marie Dingemans⁶, Anil Tibdewal⁸, Bi Nan¹¹, Spring
Fengming Kong¹², Yu Yang Soon¹, Fiona Hegi-Johnson^{7,13}, Chee Khoo Lee¹⁴, Corinne Faivre-Finn⁴, Jordi Remon¹⁵, Myung-Ju Ahn¹⁶

¹National University Cancer Institute, Singapore; ²University Hospital and Trust of Verona, Verona, Italy; ³University of Pittsburgh Medical Center, Pittsburgh, USA; ⁴The Christie NHS Foundation Trust and University of Manchester, Manchester, UK; ⁵University Hospital Virgen de la Victoria, Biomedical Research Institute of Malaga (IBIMA Plataforma Bionand), Malaga, Spain; ⁶Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands; ⁷Peter MacCallum Cancer Centre, Melbourne, Australia; ⁸Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India; ⁹Samsung Medical Center, Seoul, Republic of Korea; ¹⁰City of Hope Cancer Center Atlanta, Newnan, Georgia, USA; ¹¹National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; ¹²The University of Hong Kong-Shenzhen Hospital (HKU-SZH), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Shenzhen, China; ¹³University of Melbourne, Melbourne, Australia; ¹⁴National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney, Sydney, Australia; ¹⁵Gustave Roussy, Villejuif, France; ¹⁶Hanyang University Medical Center, Hanyang University College of Medicine, Seoul, Republic of Korea

Science Without Boundaries: **Uniting the World Against Thoracic Cancer**

Disclosure

- No conflicts of interest to be disclosed.

Study Design

Background:

LAURA and POLESTAR trials established lifelong maintenance tyrosine kinase inhibitors (TKI) following chemoradiation as the standard of care in patients with unresectable epidermal growth factor receptor (EGFR)-mutant stage III non-small cell lung cancer (NSCLC) for its progression-free survival benefit.

Objectives:


This survey aims to evaluate clinician perspectives to

1. Define baseline investigation standards
2. Identify implementation barriers, and
3. Explore preferred treatment optimization strategies


Lu et al. N Engl J Med. 2024 (LAURA); Meng et al. WCLC 2024 (POLESTAR)

Methods:

- International prospective survey
- Study period: Sep 2025 to May 2026
- Platform: SurveyMonkey via EORTC
- Worldwide dissemination of the survey across major oncologic networks and institutional multidisciplinary tumor boards



Respondent Demographics (N= 207)



Baseline Staging



FDG PET-CT (96%)



Brain MRI (76%)




Systematic Mediastinal Staging (74%)

Near-universal consensus for PET-CT.
Most advocate for brain imaging and mediastinal staging.

93% perform EGFR testing, but only 68% utilize whole-panel NGS from tissue.

Implementation Barriers & Concerns

Real-World TKI Adoption



58%

Current Lifelong Use

29% GAP

Ideal TKI Adoption (No Constraints)



87%

Desired Lifelong Use

66% express concerns regarding indefinite dosing of TKI



Financial Toxicity (78%)



Long-term Adverse Events (62%)



Lack of Mature OS Data (53%)

Future Trial Strategies

93% express interest in supporting
treatment optimisation trials

Preferred Trial Design (Rank Order)



Fixed duration vs. Indefinite therapy



77%



Risk stratification based on ctDNA MRD



61%



Delayed vs. Immediate TKI



45%


Conclusion

This global survey demonstrates

- A **strong consensus for comprehensive baseline staging.**
- **Concerns exist** regarding costs and long-term adverse events with lifelong maintenance TKI.
- A **high level of motivation** to support future trials investigating treatment optimization, with the two most preferred strategies being (1) **treatment duration** and (2) **biomarker-based risk stratification.**

An ongoing patient-centred survey developed in collaboration with patient advocates aims to capture patient perspectives and their receptivity toward treatment de-intensification trials.

- We acknowledge the support of the IASLC, EORTC, ASTRO, TROG, TOGA, ANNCA, LATAM, MACA, and affiliated oncology networks, for assisting with the dissemination of the survey.
- We thank the EORTC for providing and administering the survey platform.



*Disclosure on the use of artificial intelligence:
Infographics were designed using NotebookLM.
All scientific contents were developed and verified
by the authors.*

Thank You.

